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Abstract
Introduction—Crotonaldehyde is an α,β-unsaturated carbonyl compound that is a potent eye, 
respiratory, and skin irritant. Crotonaldehyde is a major constituent of tobacco smoke and its 
exposure can be quantified using its urinary metabolite N-acetyl-S-(3-hydroxypropyl-1-methyl)-L-
cysteine (HPMM). A large-scale biomonitoring study is needed to determine HPMM levels, as a 
measure of crotonaldehyde exposure, in the general U.S. population.
Materials and methods—Urine samples were obtained as part of the National Health and 
Nutrition Examination Survey 2005–2006 and 2011–2012 from participants who were at least six-
years-old (N = 4,692). Samples were analyzed for HPMM using ultra performance liquid 
chromatography - tandem mass spectrometry. Exclusive tobacco smokers were distinguished from 
non-tobacco users through a combination of self-reporting and serum cotinine data.
Results—Detection rate of HPMM among eligible samples was 99.9%. Sample-weighted, 
median urinary HPMM levels for smokers and non-users were 1.61 and 0.313 mg/g creatinine, 
respectively. Multivariable regression analysis among smokers showed that HPMM was positively 
associated with serum cotinine, after controlling for survey year, urinary creatinine, age, sex, race, 
poverty level, body mass index, pre-exam fasting time, and food intake. Other significant 
predictors of urinary HPMM include sex (female > male), age (children > non-user adults), race 
(non-Hispanic Blacks < non-Hispanic Whites).
Conclusions—This study characterizes U.S. population exposure to crotonaldehyde and 
confirms that tobacco smoke is a major exposure source. Urinary HPMM levels were significantly 
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higher among exclusive combusted tobacco users compared to non-users, and serum cotinine and 
cigarettes per day were significant predictors of increased urinary HPMM. This study also found 
that sex, age, ethnicity, pre-exam fasting time, and fruit consumption are related to urinary HPMM 
levels.
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INTRODUCTION
Crotonaldehyde (2-butenal), an α,β-unsaturated carbonyl compound, is a colorless liquid 
with a pungent odor. It exists as the cis and the trans isomers; commercial crotonaldehyde 
consists of >95% trans isomer (IARC, 1995). It is mainly used in the manufacturing of 
sorbic acid and n-butanol. It is a potent eye, respiratory, and skin irritant (Coenraads et al., 
1975). The occupational short term exposure limit (STEL) for crotonaldehyde is 0.3 ppm 
according to the American Conference of Governmental Industrial Hygienists (ACGIH, 
2015).
Crotonaldehyde reacts with deoxyguanosine in DNA to generate 1,N2-
propanodeoxyguanosine adducts that may lead to genetic mutations (Chung et al., 1984). 
These adducts have been found in human lung tissues (Zhang et al., 2006). In rats, 
crotonaldehyde forms non-neoplastic and neoplastic liver lesions including hepatocellular 
carcinomas (Chung and Hecht, 1986). However, no human data associates carcinogenicity 
with crotonaldehyde exposure; thus the International Agency for Research on Cancer 
classifies the compound as group 3, not classifiable as to its carcinogenicity in human 
(IARC, 1995). In contrast, the U.S. Environmental Protection Agency (EPA) lists 
crotonaldehyde as a possible human carcinogen (group C) based on limited animal data and 
supporting genotoxicity data (EPA, 1991).
A major source of crotonaldehyde exposure is cigarette smoke (Counts et al., 2004). The 
amount of the compound in cigarette smoke varies from 1–53 μg per cigarette, depending on 
the machine smoking protocol used for measurement and the cigarette brand filter 
ventilation (Pazo et al., 2016). Crotonaldehyde is also found in smokeless tobacco, engine 
exhaust, and wood combustion (Destaillats et al., 2002; IARC, 1995; Masiol and Harrison, 
2014; Stepanov et al., 2008). Crotonaldehyde occurs naturally in many foods (Feron et al., 
1991; Kensler et al., 2012), such as fruits (e.g., apples, guavas, grapes, strawberries and 
tomatoes), vegetables (e.g., cabbage, cauliflower, Brussels sprouts, carrots and celery 
leaves), dairy products (e.g., bread, cheese and milk), animal proteins (e.g., meat and fish), 
alcoholic beverages (e.g., beer and wine), heated cooking oils, and chips. Additionally, 
endogenous lipid peroxidation could result in crotonaldehyde exposures in humans (Nair et 
al., 2007; Niki, 2009; Voulgaridou et al., 2011). Crotonaldehyde can also form in vivo as a 
metabolite of N-nitrosopyrrolidine and 1,3-butadiene (Elfarra et al., 1991; Wang et al., 
1988).
Crotonaldehyde is metabolized primarily to N-acetyl-S-(3-hydroxypropyl-1-methyl)-L-
cysteine (HPMM) and to a lesser extent, 2-carboxy-1-methylethylmercapturic acid, both of 
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which are excreted via the urine in rats (Gray and Barnsley, 1971). The identification of 
HPMM as a major crotonaldehyde metabolite is supported by the HPMM structural 
homologue, N-acetyl-S-(3-hydroxypropyl)-L-cysteine (HPMA), being identified as a 
primary metabolite of crotonaldehyde’s three carbon structural homologue acrolein (Parent 
et al., 1998). Urinary HPMM levels are proportional to crotonaldehyde exposure (Carmella 
et al., 2013), and it is a useful biomarker for smoking-related exposure (Scherer et al., 2007). 
Cigarette smokers have higher urinary HPMM compared to non-smokers (Pluym et al., 
2015; Scherer et al., 2007). Carmella et al. also demonstrated that urinary HPMM decreases 
significantly in the first three days after a smoker ceases smoking (Carmella et al., 2009).
Although there are studies on crotonaldehyde exposure among smokers, there are no large-
scale biomonitoring studies assessing exposure in the general population. Moreover, the 
effect of diet on crotonaldehyde exposure has not been assessed systematically. These gaps 
prompted us to examine crotonaldehyde exposure in a representative sample of the U.S. 
population. In this study, we measured HPMM concentrations in urine samples provided by 
participants in the 2005–06 and 2011–12 cycles of the National Health and Nutrition 
Examination Survey (NHANES). Multivariable regression models were used to determine 
the influence of demographic variables (e.g., age, sex, and race) on HPMM concentrations, 
as well as the effects of certain lifestyle factors, such as obesity, tobacco use, and diet. Thus, 
this biomonitoring study characterizes crotonaldehyde exposure in the U.S. population and 
explores different exposure sources and modifiers.
MATERIAL AND METHODS
1.1. Study design
NHANES is a population-based survey designed to assess the health and nutritional status of 
adults and children in the United States (https://www.cdc.gov/nchs/nhanes/index.htm). The 
survey is based on cross-sectional observation of a complex, multistage probability sample 
representative of the civilian, non-institutionalized U.S. population. The survey collects 
questionnaire data, physical examination data, and biological samples. NHANES is 
conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease 
Control and Prevention (CDC). The study protocol was reviewed and approved by a CDC 
institutional review board, and informed written consent is obtained from all study 
participants before they participate in the study.
Spot urine samples were collected from participants in two NHANES survey cycles—a one-
half subsample of participants ≥ 12 years old from NHANES 2005–2006 and a one-third 
subsample of participants ≥ 6 years old from NHANES 2011–2012—and were measured for 
HPMM to determine crotonaldehyde exposure.
1.2. Chemical analysis
The collected urine samples were stored at −70 °C until analysis. Urinary HPMM 
concentrations were measured using ultra high performance liquid chromatography coupled 
with electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) according to a 
published procedure (Alwis et al., 2012). Briefly, urine samples were analyzed at 1:10 
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dilution (a mixture of 50 μL urine, 25 μL 2H3-HPMM internal standard, and 425 μL 15 mM 
ammonium acetate, pH 6.8). Liquid chromatography was performed using an ACQUITY 
UPLC HSS T3 Column, 1.8 μm, 2.1 mm × 150 mm, with mobile phases containing 15 mM 
ammonium acetate, pH 6.8 (solvent A) and acetonitrile (solvent B). The eluate was ionized 
using ESI technique. The mass spectrometer was operated in scheduled multiple reaction 
monitoring (SMRM) mode for negative ions; mass-to-charge (m/z) transitions were 
monitored at 234→105 for HPMM and 237→105 for the internal standard, 2H3-HPMM. 
Urinary HPMM concentrations were calculated from a linear calibration curve obtained by 
plotting the relative response factor (ratio of the peak area of native analyte to the peak area 
of the corresponding internal standard) as a function of the native standard concentration. 
The limit of detection (LOD) in urine was 2.0 ng/mL for HPMM (Alwis et al., 2012).
1.3. Statistical analysis
The crotonaldehyde metabolite HPMM was measured in spot urine samples collected from 
5,815 participants in the one-third environmental subsample of NHANES 2005–2006 and 
2011–2012. Many of these study participants were likely exposed to crotonaldehyde as a 
component of tobacco smoke; therefore we categorized tobacco smoke exposure based on a 
combination of questionnaire and serum cotinine data (Pirkle et al. 1996). Study participants 
were identified as exclusive users of combusted tobacco products (named “exclusive 
combusted tobacco users” or “exclusive tobacco smokers”) if they had serum cotinine >10 
ng/mL and responded “yes” to question SMQ680 (tobacco or nicotine use within 5 days 
prior to NHANES physical examination), “yes” to at least one of SMQ690A–SMQ690C 
(cigarettes, pipes, cigars), and “no” to all of SMQ690D–SMQ690F (smokeless tobacco and 
nicotine delivery products). Participants were identified as non-users of tobacco products if 
they answered “no” to either SMQ680 or SMD020 (smoked 100 cigarettes in life), or 
answered “never smoked cigarettes regularly” to SMD030 (age started smoking regularly). 
Non-users were confirmed by a serum cotinine measurement ≤10 ng/ml. Alternatively, 
participants missing responses for SMQ680, SMD020, and SMD030 were classified as non-
users if they had serum cotinine ≤10 ng/mL. Participants were excluded from analysis 
because of missing serum cotinine data (N = 284), for not having answered SMQ680 (230 
participants), or missing data for other variables used in the regression models (N = 609), 
leaving 4,692 study participants eligible for statistical analysis.
Reported results met the accuracy and precision specifications of the quality control/quality 
assurance program of the CDC National Center for Environmental Health, Division of 
Laboratory Sciences (Caudill et al., 2008). Measurements below the limit-of-detection 
(LOD) were imputed with the quotient of the LOD divided by the square root of two 
(Hornung and Reed, 1990).
Because NHANES participants are recruited through a multistage sampling design, it is 
necessary to account for this complex design to estimate variances properly and to produce 
unbiased, nationally representative statistics. Robust estimation may be accomplished by 
applying survey sample weights to each participant’s data and using Taylor series 
linearization to produce variance estimates. We used this estimation approach as it was 
implemented in the DESCRIPT subroutine of the statistical software package SUDAAN®, 
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Version 11.0.0 (Research Triangle Institute 2012), called from the SAS statistical software 
application, Version 9.3, as well as the SURVEYREG subroutine of SAS 9.3 (SAS Institute 
2010). Sample-weighted linear regression models stratified by tobacco use status (exclusive 
combusted tobacco users vs. non-users) were fit to NHANES data from the 2005–2006 and 
2011–2012 survey cycles (NHANES), where the dependent variable was urinary HPMM 
concentration (ng/mL). Because the distribution of urinary measurements was highly right-
skewed and would have adversely affected hypothesis testing, urinary HPMM concentration 
data were reported as geometric means and transformed with the natural log for evaluating 
the statistical significance of regression slopes. The p-values for slopes from the natural log 
of the urinary HPMM concentration regression models are reported. To facilitate 
interpretability, however, we report slopes and their 95% confidence intervals estimated from 
identical regression models of untransformed urinary concentration data. Statistical 
significance was set to α ≤ 0.05.
Potential confounders were included in the regression models: age, sex, race/ethnicity, body 
mass index (BMI), poverty level (the ratio of family income to poverty), food intake, and 
hours of pre-exam fasting. Information for these potential confounders was self-reported. 
Age (year) was categorized into the following ranges: 6–11, 12–19, 20–39, 40–59, and ≥ 60. 
While standard definitions for underweight (BMI < 18.5), healthy weight (18.5 ≤ BMI < 
25), and overweight/obese (BMI ≥ 25) applied to adults 20 years of age and older, 
participants younger than 20 were classified as underweight, healthy weight, and 
overweight/obese if they were below the 5th percentile, between the 5th and 85th percentile, 
and above the 85th percentile, respectively, for their sex and age (https://www.cdc.gov/
healthyweight/assessing/bmi). Poverty level was determined by whether the ratio of a 
family’s income to poverty (INDFMPIR) was greater or less than the poverty threshold, 
which is represented by the ratio of 1, according to NHANES (https://www.cdc.gov/nchs/
nhanes/index.htm).
Food intake was reported with a 24-hour dietary recall on the same day blood and urine 
samples were taken (DR1IFF_G). Each food recalled was reported by NHANES with a 
quantity, nutritional information, and an 8-digit code, which uniquely identifies the type of 
food in the USDA Food and Nutrient Database for Dietary Studies (FNDDS) database. 
Regression variables were produced by summing the mass of the individual food group 
consumed by each participant, with any participant reporting no consumption given a zero. 
Food categories consist of nine food groups identified by the USDA corresponding to the 
first digit of the FNDDS food code as well as the following independently derived 
categories. The smoked meat category was constructed based on the USDA’s “What’s in the 
Foods You Eat” search tool and by using the search term “smoked,” “barbecue” (which is 
synonymous with smoking), and “pastrami” (which is by definition smoke-cured) and 
including all dishes. The brewed coffee category was constructed by using the search term 
“coffee” and including drinks that are mostly coffee (e.g., regular coffee and espresso), but 
excluding things such as lattes that are mostly milk. The cruciferous vegetables category was 
constructed by using every vegetable listed on the Wikipedia page for cruciferous vegetables 
as a search term. Self-reported hours of pre-exam fasting was included in the model as a 
continuous predictor and potential confounder of the association between diet and 
crotonaldehyde exposure, ranging as high as several days.
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In addition, urinary biomarker concentrations can be influenced by urine dilution, which can 
vary markedly from void to void and may confound statistical inference (Barr et al., 2005). 
Urine dilution can be accounted for by scaling urinary analyte concentration to the urinary 
concentration of creatinine, a compound formed endogenously by lean body mass and 
excreted at a fairly constant rate. Summary statistics of urinary concentrations are reported 
as the ratio of HPMM to creatinine (mg/g creatinine). For the regression models, however, 
we accounted for urinary dilution by including urinary creatinine (mg/dL) as a model 
predictor.
Serum cotinine was used as a continuous variable to evaluate the association between 
urinary HPMM concentration and tobacco smoke exposure in the regression model for both 
exclusive combusted tobacco users and non-users. Among non-users, tobacco smoke 
exposure is primarily attributed to second-hand smoke (SHS), which is associated with 
serum cotinine levels in the range of 0.05–10 ng/mL (Homa et al., 2015). To directly 
associate urinary biomarker concentrations with the frequency of cigarette smoking, we ran 
the same regression model but replaced serum cotinine with self-reported average number of 
cigarettes smoked per day (CPD) over the five days preceding the exam. We kept the dual 
users, who reported CPD as well as use of other combusted tobacco products, in this model 
to maintain consistency throughout the study. This variable was classified in ranges of 1–10 
CPD (0.5 pack), 11–20 (1 pack), and > 20 (> 1 packs), where the reference category was 
comprised of participants with serum cotinine ≤ 0.05 ng/mL. CPD was only assigned in 
subjects with no missing cotinine values. In the CPD model, participants were excluded if 
they were neither exclusive combusted tobacco users nor non-users (N = 230), could not be 
assigned a CPD value (N = 499), or had missing data for other variables used in the 
regression model (N = 584 participants), leaving 4,502 participants eligible for statistical 
analysis.
RESULTS
HPMM was detected in 99.9% of the urine samples measured in NHANES 2005–2006 and 
2011–2012 cycles. Shown in Table 1 are sample-weighted demographic distributions for this 
study for exclusive combusted tobacco users (~20% of the population) and non-users.
Sample-weighted summary statistics for urinary HPMM concentrations among participants 
are presented in Table 2. A detailed analysis is available in the online supplementary 
material (Table A.2 for non-users and Table A.3 for exclusive combusted tobacco users). The 
median urinary HPMM concentration for exclusive combusted tobacco users (1.63 mg/g 
creatinine) was higher than for non-users (0.313 mg/g creatinine). We observed the similar 
shift in median HPMM level (the green bar) in Figure 1, which shows the percentage 
distribution of HPMM among combusted tobacco smokers and non-users. In this figure, the 
distribution among tobacco smokers shows a bimodality, which is only present for the 
creatinine-adjusted HPMM data.
The median value of urinary HPMM concentrations typically increased with age except 
among non-users aged 6–11, who had the highest concentration of HPMM among the non-
users. Interestingly, median concentration of HPMM was higher among females compared 
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with males for both exclusive combusted tobacco smokers and non-users. Among different 
racial groups, Mexican Americans and non-Hispanic Blacks had the lowest concentration of 
urinary HPMM among exclusive combusted tobacco users and non-users respectively, 
whereas non-Hispanic Whites had the highest levels in both groups. In an unstratified 
multivariable regression model, urinary HPMM was significantly higher by 2214 ng/mL 
among exclusive smokers compared to non-users, controlling for survey year, urinary 
creatinine, age, sex, race, poverty level, body mass index, pre-exam fasting time, and food 
intake.
Results of the multivariable regression analysis for non-users are shown in Table 3. In this 
model, serum cotinine was not a strong predictor (p = 0.0823) of urinary HPMM 
concentrations after controlling for survey year, urinary creatinine, age, sex, race/ethnicity, 
BMI, poverty level, food intake, and pre-exam fasting time. The model also showed no sex 
differences between female and male subjects (p = 0.0616). Using the age group 20–39 as a 
reference, we determined that HPMM levels were significantly higher among all age groups, 
except 12–19, which was not significantly different. When non-users were grouped 
according to race, only non-Hispanic blacks (p < 0.0001) had statistically lower HPMM 
values compared with non-Hispanic whites. Subjects’ BMI and poverty status had no effect 
on urinary HPMM excretion. Among different food categories, only fruits (p = 0.0014) 
showed significant positive correlations with HPMM levels. Pre-exam fasting time showed 
strong negative correlation (p < 0.0001) with urinary HPMM excretion.
Results of multivariable regression analysis for the exclusive combusted tobacco smokers 
are presented in Table 4. In contrast to non-users, serum cotinine in exclusive combusted 
tobacco users, was a strong predictor (p = 0.0014) of urinary HPMM concentrations after 
controlling for other regression variables. The model also showed sex differences: female 
subjects (p = 0.0135) had significantly higher HPMM levels compared with males. Using the 
age group 20–39 as a reference, we determined that HPMM levels were significantly lower 
for the group 12–19 (p = 0.0048), whereas they were higher for both 40–59 (p = 0.0001) and 
≥ 60 (p = 0.0003) groups. When these smokers were grouped according to race, Mexican 
Americans (p = 0.0104) and non-Hispanic Blacks (p < 0.0001) had significantly lower 
HPMM values compared with non-Hispanic whites. Subjects below the poverty level had 
significantly higher levels of HPMM in their urine samples (p = 0.0007) compared with 
those above poverty level. When compared with healthy weight individuals, overweight (p = 
0.0365) populations had significantly lower urinary HPMM concentrations. Unlike non-
users, fruits were not a strong predictor of HPMM concentrations among exclusive 
combusted tobacco users. Pre-exam fasting time showed strong negative correlation (p = 
0.0003) with urinary excretion of HPMM among tobacco smokers as well.
Since serum cotinine showed a significant positive correlation with urinary HPMM 
concentrations among exclusive combusted tobacco users, we also examined the relationship 
between the metabolite and CPD. Figure 2 shows that HPMM level increases with 
increasing CPD.
We further ran a multivariable regression model combining exclusive combusted tobacco 
users and non-users, where the variable cotinine was replaced by CPD (Table A.1). When 
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adjusted for survey year, urinary creatinine, age, sex, race/ethnicity, BMI, poverty level, food 
intake, and pre-exam fasting time, Table A.1 showed that all exclusive combusted tobacco 
users had significantly higher urinary HPMM levels compared with subjects with no tobacco 
smoke exposure (cotinine ≤ 0.05 ng/mL). Similar to Figure 2, a dose-dependent increment of 
slope was observed with respect to CPD. The variables, sex and BMI, followed similar 
trends as described in the model in Table 4 for exclusive combusted tobacco users. For 
example, females had higher HPMM levels than men, and overweight people had lower 
levels than healthy individuals. Similar to non-users (Table 3), all age groups had 
significantly higher HPMM levels compared with the group aged 20–39, except for the 12–
19 year olds, who were not statistically different. Only non-Hispanic Blacks had 
significantly lower HPMM values than the non-Hispanic Whites. Fruits (p = 0.0327) showed 
significant positive correlation with HPMM levels, as seen among non-users. Likewise, pre-
exam fasting time was negatively correlated with HPMM concentrations.
Additionally, crotonaldehyde is a homologue of acrolein (α,β-unsaturated aldehydes), and 
both are major components of cigarette smoke; thus exposure to those two aldehydes will 
likely be positively correlated. Similar to crotonaldehyde, the majority of absorbed acrolein 
is metabolized and excreted in the urine as mercapturic acid conjugates, HPMA as well as 
CEMA (Parent et al., 1998). Therefore, we investigated the correlations between their 
respective metabolites, HPMM from crotonaldehyde and HPMA and CEMA from acrolein 
(Figure 3). Both HPMA (coefficient = 0.81) and CEMA (coefficient = 0.63) showed strong 
correlations with HPMM.
DISCUSSION
In this report, the detection rate of HPMM was 99.9% of urine samples collected from a 
representative sampling of the U.S. population. This finding likely reflects widespread 
population exposure to crotonaldehyde from endogenous sources, such as lipid peroxidation 
(Nair et al., 2007; Niki, 2009; Voulgaridou et al., 2011), and exogenous sources, including 
vehicle exhaust (Destaillats et al., 2002), diet (Feron et al., 1991), and tobacco smoke (Pazo 
et al., 2016).
In this first biomonitoring evaluation of crotonaldehyde exposure in the U.S. population, we 
find that tobacco smoke is a major source of crotonaldehyde exposure: the median value of 
HPMM in exclusive combusted tobacco users was five times higher than in non-users (Table 
2). The percentage distribution of the population depicted a similar median shift between 
tobacco smokers and non-users (Figure 1). Furthermore, among exclusive combusted 
tobacco users, data analysis revealed a significant correlation between HPMM and serum 
cotinine (Table 4), and HPMM and CPD (Figure 2 and Table A.1).
As shown in Table 2, children (6–11 YO) had the highest urinary HPMM levels of non-
users. This trend persisted even after adjusting for other important predictors, such as 
creatinine and cotinine, in the model in Table 3. This could be due to their relatively larger 
surface area to body weight ratio, which can lead to higher toxicant exposure dose in 
children compared with adults (Bearer, 1995). Another explanation is that young children 
have higher levels of crotonaldehyde exposure because they have higher levels of 
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secondhand smoke exposure compared with older age groups (CDC, 2010). It is also of note 
that in all three regression models (Tables 3, 4, and A.1), non-Hispanic Blacks had 
significantly lower HPMM concentrations compared with non-Hispanic Whites. Such 
differences among racial groups were also observed by Park et al. (Park et al. 2015). 
Additionally, female smokers had significantly higher HPMM levels than their male 
counterparts (Table 4). This sex-related bias could result from the sex differences in 
pharmacodynamics and pharmacokinetics often observed in drug metabolism (Soldin and 
Mattison, 2009). Another source of the differences in urine HPMM levels among different 
non-user subpopulations could be endogenous formation of crotonaldehyde during oxidation 
of lipids by reactive oxygen/nitrogen species; for example different race/ethnicities may 
have different rates of inflammatory conditions such as Crohn’s Disease (Nair et al., 2007; 
Niki, 2009; Voulgaridou et al., 2011). Researchers suggested that ω-3 polyunsaturated fatty 
acids may be the main precursor of endogenous crotonaldehyde and its subsequently formed 
DNA adduct (i.e., 1,N2-propano-2′-deoxyguanosine) (Pan and Chung, 2002). However, 
because 1,N2-propano-2′-deoxyguanosine can also be generated from DNA adduct 
formation with two acetaldehyde molecules (Wang et al., 2000), its in vivo utility as an 
exposure biomarker for either endogenous or background crotonaldehyde remains uncertain.
BMI and income to poverty ratio variables were significant predictors of HPMM in smokers, 
but not in non-users (Table 4). The lack of consistency of these associations between the two 
models indicates that these findings may be spurious. However, obesity has previously been 
associated with decreased smoke exposure biomarkers in cotinine-adjusted models of 
smokers (Vesper et al., 2013). Obese smokers had significantly lower HPMM concentrations 
than healthy weight individuals (Table 4). Another predictor that was only significant in the 
smoker model is poverty: Tobacco smokers below the poverty level had significantly higher 
HPMM concentrations compared with smokers above poverty level (Table 4). This 
difference may be attributable to other lifestyle factors, such as usage of alcohol, medicines, 
and other smoked products (e.g. hookah or marijuana), which could affect crotonaldehyde 
exposure and the pharmacokinetic profiles of absorbed crotonaldehyde.
As described above, almost everybody in the population would have detectable levels of 
HPMM in their urine. In part, this could be due to the natural occurrence of crotonaldehyde 
in diets (Feron et al., 1991). In order to identify different dietary exposure sources of 
crotonaldehyde, we included several food groups in our regression model. Among different 
food groups, fruits showed significant positive correlation with HPMM concentrations in 
non-users (Table 3). This finding corroborates the existing literature listing many fruits—
such as apples, guavas, grapes, strawberries and tomatoes—as natural sources of 
crotonaldehyde (Feron et al., 1991). In the model for exclusive combusted tobacco users, the 
effect of fruits was not significant, possibly because the magnitude of crotonaldehyde from 
fruit intake is less than the magnitude from tobacco smoke. We also evaluated the possibility 
that consumption of alcohol, toast, or smoked foods could affect urinary HPMM, but found 
no relation (data not shown). The overall relevance of dietary intake of crotonaldehyde was 
underscored by the finding that urinary HPMM level decreased with increasing fasting time 
in all models (Tables 3, 4, and A.1).
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Crotonaldehyde is a homologue of acrolein, and thus is similarly formed (e.g. pyrolysis or 
combustion) and metabolized (e.g., formation of glutathione conjugates and DNA adducts) 
(Horiyama et al., 2016; Pan and Chung, 2002). Both α,β-unsaturated aldehydes are major 
components of cigarette smoke (Pazo et al., 2016) and could be formed endogenously as a 
byproduct of lipid peroxidation (Nair et al., 2007; Niki, 2009; Voulgaridou et al., 2011). As 
expected based on the common formation and metabolism of these aldehydes, significant 
correlations were found between the urinary metabolites of crotonaldehyde (HPMM) and 
acrolein (HPMA and CEMA).
The strengths of this study include the robust characterization of crotonaldehyde exposure 
(by measuring its urinary metabolite HPMM), as it examined tobacco users and non-users in 
a large representative sampling of the U.S. population (NHANES participants). The 
NHANES study is conducted as a series of surveys focusing on different population groups 
or health topics in a sustainable and reliable manner. Because NHANES is an ongoing 
program, the information collected contributes to annual estimates in topic areas included in 
the survey. For small population groups and less prevalent conditions and diseases, data must 
be accumulated over several years to provide adequate estimates. The continuous design 
allows increased flexibility in survey content (https://www.cdc.gov/nchs/nhanes/
about_nhanes.htm). Our study focuses on the two latest available surveys surveying VOC 
metabolites in urine (2005–2006–2011–2012).
Our study, however, suffers from some limitations. We report on crotonaldehyde exposure as 
determined by metabolite quantification after in vivo crotonaldehyde epoxidation, followed 
by glutathione conjugation, rather than measurements of native crotonaldehyde. However, 
since crotonaldehyde is a reactive species, its native presence in biological fluids may not 
provide useful information about the extent of exposures. Additionally, the NHANES study 
is cross-sectional, where participants are selected to be representative of the U.S. population, 
and may occasionally not be representative. Nevertheless, the sample study size minimizes 
these occurrences, providing reliable estimates of environmental exposures, dietary and 
smoking information on the U.S. population.
CONCLUSIONS
This report characterizes the urinary levels of HPMM in a representative sample of the U.S. 
population and validates tobacco smoke as a major source of crotonaldehyde exposure. 
Demographic variables, such as age, sex and race, showed distinct effects on crotonaldehyde 
exposure. Although crotonaldehyde naturally occurs in many foods, increased urinary 
HPMM was significantly associated only with fruit consumption among non-users, but not 
in exclusive combusted tobacco users, suggesting the magnitude of crotonaldehyde from 
fruit intake is less than the magnitude from tobacco smoke. Future work could possibly 
elucidate differences in urinary HPMM excretion and hence potential toxicological effects of 
crotonaldehyde related to different variables (e.g., age, sex, race, and diet). Additionally, 
analysis of urinary HPMM in future NHANES cycles will allow us to track changes in 
crotonaldehyde exposure pertaining to potential regulatory/policy changes.
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Fig. 1. 
Percentage distribution (not sample-weighted) of urinary HPMM concentrations (μg/g 
creatinine) among non-users and exclusive combusted tobacco users. Urinary HPMM 
concentration data were log (base 10) transformed.
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Fig. 2. 
Least-square means of urinary HPMM concentrations for different numbers of cigarettes 
smoked per day (CPD) categories, adjusted for all other regression variables (e.g., age, sex, 
race/ethnicity, etc.).
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Fig. 3. 
Scatterplot diagrams showing correlations between HPMA and HPMM (a) & CEMA and 
HPMM (b). Data were adjusted for urinary creatinine and log (base 10) transformed.
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Table 2
Sample-weighted median (25th, 75th percentile) urinary HPMM concentrations (mg/g creatinine).
Variable Level Exclusive Combusted Tobacco Users Non-Users
All 1.63 [0.680, 3.29] 0.313 [0.231, 0.451]
Age (yr) 6–11 N/A 0.423 [0.324, 0.511]
12–19 0.607 [0.398, 1.32] 0.259 [0.204, 0.350]
20–39 1.17 [0.552, 2.16] 0.275 [0.211, 0.400]
40–59 2.25 [0.936, 4.04] 0.329 [0.241, 0.479]
≥ 60 2.24 [1.12, 4.09] 0.375 [0.277, 0.542]
Sex Male 1.28 [0.580, 2.62] 0.290 [0.218, 0.414]
Female 2.03 [0.910, 3.92] 0.332 [0.245, 0.484]
Race/Ethnicity Non-Hispanic White 1.88 [0.836, 3.62] 0.330 [0.239, 0.476]
Mexican American 0.694 [0.369, 1.82] 0.306 [0.227, 0.423]
Non-Hispanic Black 1.07 [0.489, 1.87] 0.253 [0.195, 0.356]
Other Race - Including Multi-Racial 1.44 [0.394, 2.61] 0.303 [0.236, 0.459]
BMI Underweight 1.73 [1.09, 4.28] 0.385 [0.249, 0.444]
Healthy weight 1.97 [0.863, 3.45] 0.323 [0.235, 0.486]
Overweight/Obese 1.44 [0.626, 3.02] 0.306 [0.227, 0.426]
Poverty Status No 1.57 [0.655, 3.31] 0.316 [0.232, 0.453]
Yes 1.67 [0.906, 3.20] 0.297 [0.227, 0.434]
BMI: Body mass index
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Table 3
Sample-weighted multiple regression slopes for urinary HPMM concentrations among non-users (N = 3825). 
The p-value was estimated from identical models, where the dependent variable was natural log-transformed.
 Predictor Level Slope [95% CI] p-Value
 Intercept 84.18 [−35.44:203.80] < 0.0001
 NHANES Cycle 2005–2006 −96.50 [−143.71: −49.29] < 0.0001
2011–2012 Ref.
 Creatinine, urine [mg/dL] Slope 3.47 [3.08:3.87] < 0.0001
 Cotinine, serum [ng/mL] Slope 18.52 [−3.53:40.58] 0.0823
 Age (yr) 6–11 109.22 [22.28:196.16] 0.0007
12–19 0.37 [−66.98:67.72] 0.5339
20–39 Ref.
40–59 120.89 [44.08:197.71] 0.0002
≥ 60 211.67 [147.82:275.52] < 0.0001
 Sex Male Ref.
Female 62.49 [13.42:111.55] 0.0616
 Race/Ethnicity Non-Hispanic White Ref.
Mexican American 72.52 [5.07:139.97] 0.1313
Non-Hispanic Black −115.88 [−167.27: −64.49] < 0.0001
Other Race - Including Multi-Racial 2.07 [−56.25:60.39] 0.6281
 BMI Underweight 125.80 [−195.61:447.21] 0.5463
Healthy weight Ref.
Overweight/Obese −23.22 [−59.77:13.33] 0.1618
 Poverty Status No Ref.
Yes 57.85 [−20.89:136.59] 0.6539
Milk Products [kg] Slope −19.18 [−141.52:103.15] 0.9556
Meat, Poultry [kg] Slope −27.80 [−114.76:59.17] 0.8175
Eggs [kg] Slope −87.83 [−490.49:314.83] 0.8060
Legumes, Nuts, Seeds [kg] Slope 70.68 [−75.28:216.64] 0.2989
Grain Products [kg] Slope 57.50 [−6.55:121.55] 0.0952
Fruits [kg] Slope 136.79 [71.09:202.49] 0.0014
Vegetables [kg] Slope −12.26 [−109.85:85.33] 0.7297
Fats, Oils, Salad Dressings [kg] Slope −107.74 [−929.65:714.17] 0.6119
Sugars, Sweets, Beverages [kg] Slope 3.66 [−8.17:15.49] 0.3400
Pre-exam Fasting Time [hr] Slope −18.91 [−22.49: −15.33] < 0.0001
CI: Confidence interval; BMI: Body mass index
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Table 4
Sample-weighted multiple regression slopes for urinary HPMM concentrations among exclusive combusted 
tobacco users (N=867). The p-value was estimated from identical models, where the dependent variable was 
natural log-transformed.
 Predictor Level Slope [95% CI] p-Value
 Intercept −377.44 [−1378.76:623.88] < 0.0001
 NHANES Cycle 2005–2006 −42.51 [−359.69:274.67] 0.4540
2011–2012 Ref.
 Creatinine, urine [mg/dL] Slope 15.47 [12.37:18.56] < 0.0001
 Cotinine, serum [ng/mL] Slope 4.49 [1.80:7.17] 0.0014
 Age (yr) 6–11 N/A
12–19 −508.62 [−1109.69:92.45] 0.0048
20–39 Ref.
40–59 965.23 [672.74:1257.71] 0.0001
≥ 60 1248.30 [442.67:2053.93] 0.0003
 Sex Male Ref.
Female 553.52 [119.90:987.14] 0.0135
 Race/Ethnicity Non-Hispanic White Ref.
Mexican American −674.53 [−1206.22: −142.84] 0.0104
Non-Hispanic Black −843.50 [−1227.95: −459.05] < 0.0001
Other Race - Including Multi-Racial −111.66 [−1174.11:950.80] 0.2247
 BMI Underweight 1034.52 [−352.87:2421.92] 0.1140
Healthy weight Ref.
Overweight/Obese −317.85 [−623.53: −12.16] 0.0365
 Poverty Status No Ref.
Yes 359.93 [−32.77:752.64] 0.0007
Milk Products [kg] Slope −43.87 [−482.02:394.29] 0.9142
Meat, Poultry [kg] Slope −391.24 [−1214.25:431.77] 0.3726
Eggs [kg] Slope −419.65 [−4193.11:3353.82] 0.1078
Legumes, Nuts, Seeds [kg] Slope −523.58 [−3164.64:2117.48] 0.4399
Grain Products [kg] Slope −62.57 [−783.57:658.43] 0.1558
Fruits [kg] Slope −403.66 [−903.36:96.04] 0.0582
Vegetables [kg] Slope −783.27 [−1769.90:203.35] 0.1181
Fats, Oils, Salad Dressings [kg] Slope −4712.55 [−10261.80:836.69] 0.3549
Sugars, Sweets, Beverages [kg] Slope 60.88 [−38.93:160.68] 0.8801
Pre-exam Fasting Time [hr] Slope −61.88 [−89.67: −34.09] 0.0003
CI: Confidence interval; BMI: Body mass index
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